Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
In March 2021, we shared the news that the US Preventative Services Task Force (USPSTF) updated their lung cancer screening recommendations to include an additional 7 million current and former smokers. Today, we’re excited to see that Aetna, a commercial insurer covering 39 million Americans,
IONIQ Sciences has been designated a “Leading Pioneer in Non-Invasive Lung Cancer Testing” for the year 2021 by Global Health and Pharma. This award was given to us based on our pioneering efforts in using bioimpedance to catch cancer in its earliest stages. Our breakthrough-designated
The Utah Business magazine has recently featured IONIQ Sciences, highlighting everything from the “breakthrough” status of our IONIQ ProLung Test™ to the encouraging early results of our ongoing breast feasibility study. The article describes our key involvement with BioHive and the success we’ve had attracting world-renowned experts to help us detect
